뉴스&이벤트

RenMab™ Mouse Platform Drives SARS CoV-2 Neutralizing Antibody Cocktail Therapy Towards Clinical Trials in Biocytogen and Eucure Biopharma Partnership

[MA, USA and Beijing, China – August] The COVID-19 pandemic has been an inescapable, lethal, and overwhelming aspect of daily human life, threatening health and safety on a global scale. Biocytogen is excited to announce a breakthrough in scientific rese

더 읽어보기
PEGS Europe 2019

Biocytogen has recently developed RenMab™ Mouse, a fully human antibody mouse with its entire variable regions replaced by human Ig heavy chain and light chain.

더 읽어보기
Emerging biotechnology company Biocytogen raised 142 million dollars (USD) in support of Project Integrum

BEIJING and BOSTON, Sept. 24, 2020 /PRNewswire/ -- In August, Beijing Biocytogen Biotechnology Co., Ltd. ("Biocytogen") announced acquisition of Eucure Biopharma, which established Biocytogen as a clinical stage…

더 읽어보기
Experts in Genetically Engineered Animal Development and Maintenance

Time: 10:30-11:30am, Sept. 19th, 2019 Location: Conference Room D1, Building 114, Massachusetts General Hospital, 16th Street, Charlestown MA 02129

더 읽어보기
Biocytogen Closes $79M Series D Funding

On August 2019, Beijing Biocytogen Co., Ltd. (“Biocytogen”) announced the closing of its Series D funding of $79M (RMB 543M).

더 읽어보기
Biocytogen at the at the European Society for Medical Oncology (ESMO) 2018 annual meeting

Biocytogen is excited to exhibit at the European Society for Medical Oncology (ESMO) 2018 annual meeting, which will take place in Munich, Germany from between 19-23 October 2018!

더 읽어보기
Biocytogen’s RenMab™ Mouse is Featured on Fiercebiotech

FierceBiotech and its family of publications provide end-to-end coverage of biotech and medtech, from pre-clinical science through clinical testing and regulatory approval—and all the seed funding, venture capital, licensing deals, IPOs and M&A that h

더 읽어보기
Biocytogen’s President & CEO, Dr. Yuelei Shen, Speaks at Harvard China Forum at Harvard Universi

Biocytogen’s President & CEO, Dr. Yuelei Shen, WuXi AppTec’s US CEO, Dr. Richard Connell, and BlackRock’s healthscience fund manager, Dr. Erin (Hongying) Xie, were invited to speak at the conference’s Pharmaceuticals Panel by the panel moderator Ms.

더 읽어보기
Biocytogen at the ESMO 2018 Annual Meeting

Biocytogen at the at the ESMO 2018 annual meeting, which will take place in Munich, Germany from between 19-23 October 2018

더 읽어보기
American Association for Cancer Research (AACR) Annual Meeting 2019

10 Posters highlight new IO targets (e.g. CTLA-4, OX40, CD3e), preclinical services, PK/PD studies, and antibody screening platform will be presented at AACR.

더 읽어보기
Back to top
카카오톡 상담하기